Breaking the Ceiling: A New Strategy for IBD Treatment

For many with inflammatory bowel disease, biologic therapies have been a game-changer. Yet, a worrying trend has emerged where the efficacy of these treatments progressively declines, creating what researchers term a “therapeutic ceiling”. This limits how well patients can be treated in the long run.

A recent analysis highlights the reasons for this, pointing to the development of pharmacologic, immunologic, and cellular resistance. The body essentially learns to fight back against the medicine, rendering it less effective. To break through this ceiling, the authors propose a significant strategic shift.

They advocate for early intervention guided by biomarkers—specific biological signs—and a “mechanistically informed sequencing” of drugs. This means not just treating early, but choosing the order of treatments based on how they work, aiming to preserve their power for as long as possible and secure a better long-term therapeutic response.